Wolverine Trading’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $21.5M | Buy |
54,400
+1,800
| +3% | +$752K | 0.02% | 563 |
|
|
2025
Q2 | $23.2M | Buy |
52,600
+9,900
| +23% | +$4.56M | 0.02% | 429 |
|
|
2025
Q1 | $21M | Sell |
42,700
-7,600
| -15% | -$3.54M | 0.02% | 399 |
|
|
2024
Q4 | $20.1M | Buy |
50,300
+18,000
| +56% | +$8.34M | 0.02% | 463 |
|
|
2024
Q3 | $15M | Sell |
32,300
-4,300
| -12% | -$2.07M | 0.02% | 523 |
|
|
2024
Q2 | $17.2M | Sell |
36,600
-28,800
| -44% | -$12.5M | 0.02% | 437 |
|
|
2024
Q1 | $27.3M | Sell |
65,400
-5,400
| -8% | -$2.28M | 0.03% | 330 |
|
|
2023
Q4 | $28.8M | Buy |
70,800
+32,200
| +83% | +$11.9M | 0.03% | 347 |
|
|
2023
Q3 | $13.4M | Buy |
38,600
+26,500
| +219% | +$9.27M | 0.01% | 521 |
|
|
2023
Q2 | $4.21M | Buy |
12,100
+1,700
| +16% | +$573K | 0.01% | 1005 |
|
|
2023
Q1 | $3.25M | Sell |
10,400
-8,100
| -44% | -$2.43M | 0.01% | 1081 |
|
|
2022
Q4 | $5.34M | Buy |
18,500
+8,400
| +83% | +$2.56M | 0.01% | 870 |
|
|
2022
Q3 | $2.96M | Sell |
10,100
-9,400
| -48% | -$2.7M | ﹤0.01% | 1141 |
|
|
2022
Q2 | $5.47M | Sell |
19,500
-7,800
| -29% | -$2.09M | 0.01% | 779 |
|
|
2022
Q1 | $7M | Buy |
27,300
+500
| +2% | +$119K | 0.01% | 882 |
|
|
2021
Q4 | $5.96M | Sell |
26,800
-4,400
| -14% | -$856K | 0.01% | 1034 |
|
|
2021
Q3 | $5.68M | Sell |
31,200
-11,400
| -27% | -$2.23M | 0.01% | 1203 |
|
|
2021
Q2 | $8.38M | Buy |
42,600
+19,000
| +81% | +$3.97M | 0.01% | 784 |
|
|
2021
Q1 | $5.03M | Sell |
23,600
-20,700
| -47% | -$4.55M | 0.01% | 1107 |
|
|
2020
Q4 | $10.3M | Buy |
44,300
+5,100
| +13% | +$1.17M | 0.02% | 655 |
|
|
2020
Q3 | $10.6M | Sell |
39,200
-10,200
| -21% | -$2.81M | 0.03% | 511 |
|
|
2020
Q2 | $14.1M | Sell |
49,400
-12,300
| -20% | -$3.33M | 0.04% | 347 |
|
|
2020
Q1 | $14.3M | Buy |
61,700
+7,400
| +14% | +$1.7M | 0.04% | 311 |
|
|
2019
Q4 | $11.9M | Buy |
54,300
+14,200
| +35% | +$2.87M | 0.03% | 595 |
|
|
2019
Q3 | $6.69M | Sell |
40,100
-6,700
| -14% | -$1.19M | 0.02% | 709 |
|
|
2019
Q2 | $8.58M | Sell |
46,800
-6,900
| -13% | -$1.21M | 0.02% | 603 |
|
|
2019
Q1 | $9.88M | Sell |
53,700
-7,800
| -13% | -$1.44M | 0.03% | 503 |
|
|
2018
Q4 | $9.93M | Buy |
61,500
+30,400
| +98% | +$5.27M | 0.03% | 478 |
|
|
2018
Q3 | $5.99M | Buy |
31,100
+23,100
| +289% | +$4.11M | 0.01% | 855 |
|
|
2018
Q2 | $1.3M | Hold |
8,000
| – | – | ﹤0.01% | 1985 |
|
|
2018
Q1 | $1.3M | Sell |
8,000
-4,200
| -34% | -$686K | ﹤0.01% | 1985 |
|
|
2017
Q4 | $1.83M | Sell |
12,200
-16,700
| -58% | -$2.47M | 0.01% | 1631 |
|
|
2017
Q3 | $4.39M | Buy |
+28,900
| New | +$4.35M | 0.02% | 847 |
|
|
2016
Q4 | – | Sell |
-36,300
| Closed | -$3.09M | – | 5247 |
|
|
2016
Q3 | $3.09M | Buy |
36,300
+15,500
| +75% | +$1.46M | 0.01% | 1016 |
|
|
2016
Q2 | $1.77M | Buy |
+20,800
| New | +$1.8M | 0.01% | 1189 |
|
Other funds holding VRTX
Wolverine Trading's VRTX Position: Q3 2025 in Review
Wolverine Trading increased its Vertex Pharmaceuticals (VRTX) stake by 16% in Q3 2025, buying an estimated $1.19M and bringing the position to 20,449 shares worth $8.08M. The position accounts for 0.01% of the portfolio, ranked #1054.
Wolverine Trading first reported a position in VRTX in Q3 2017 and has held it in 24 quarters since. The position peaked at $11.9M in Q4 2023. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.
- Wolverine Trading held 20,449 shares of Vertex Pharmaceuticals worth $8.08M as of Q3 2025.
- Wolverine Trading bought 2,854 Vertex Pharmaceuticals shares in Q3 2025, an estimated $1.19M.
- Vertex Pharmaceuticals made up 0.01% of Wolverine Trading's portfolio in Q3 2025, its #1054 holding.
- Wolverine Trading first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 24 quarters since.
- Wolverine Trading's Vertex Pharmaceuticals position peaked at $11.9M in Q4 2023.
- 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.